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of life (HRQOL) from early detection of cervical cancer. Methods: A
consecutive, cross-sectional sample of 421 patients with cervical
cancer was administered the World Health Organization Quality of
Life-brief version questionnaires. A nationwide sample of 22,543
patients with invasive cervical cancer (ICC) was collected from the
national cancer registry for estimation of lifetime survival function
from 1998 to 2007, which was further multiplied by the ratio of HRQOL
score functions for patients with ICC and patients with carcinoma
in situ (CIS), and summed up over lifetime to obtain expected relative-
quality-adjusted survival. The difference between lifetime survival
and the expected relative-quality-adjusted survival gives the expected
total dissatisﬁed time during the life course. Results: In comparison
with patients with CIS postconization, patients with ICC showed
consistently lower scores in the physical and psychological domains
and that of sexual life after adjustment for other risk factors. Thenternational Society for Pharmacoeconomics and
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Open access under CC BY-NC-ND license.expected years of life lost for an invasive cancer was 6.48 years
using the general population as the reference cohort, while the
durations of equivalent to living with a very dissatisﬁed HRQOL were
1.71 and 0.25 for the physical and psychological domains, respectively,
and 1.47 years for sexual life. Validation of the extrapolation method
based on a subcohort followed from the 6th to the 13th year shows a
relative bias of 0.4%. Sensitivity analysis with 37,000 CIS cases as the
reference cohort yields a similar result. Conclusions: Early detection
of cervical cancer not only avoids premature mortality but also
prevents long-term living under lower HRQOL scores, including
sexual life.
Keywords: cervical cancer, living with very dissatisﬁed HRQOL, health-
related quality of life (HRQOL), relative-quality-adjusted survival.
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Cervical cancer is one of the most prevalent types of cancer in
women and is responsible for 528,000 annual cases worldwide [1].
As a result of widespread screening programs coupled with
advanced medical treatment technology, women with cervical
cancer now have relatively high 5-year survival rates [2], and
there is a consensus that early detection of cervical cancer can
avoid premature mortality [3]. The Taiwanese government
launched a nationwide cervical screening program in July 1995
in which annual Papanicolaou test screenings were offered to
women older than 30 years. Recent records from 2009 indicate
that the compliance rate for Papanicolaou test is approximately
50% by age 65 years, which drops down to 30.5% at age 70 years orolder [4]. As the life expectancy is about 20 years for an average
case of invasive cervical cancer (ICC) in Taiwan [5], the potential
long-term gain in the health-related quality of life (HRQOL) may
create additional incentives for cancer treatment and screening
[6]. Although there are studies exploring the HRQOL for different
treatment modalities among patients with ICC [7–10], few have
quantiﬁed the duration of potential gain in the HRQOL from
direct comparison with patients with carcinoma in situ (CIS).
In this study, we recruited patients with CIS postconization as
the reference group and performed repeated measurements on
the HRQOL after diagnosis during the management of ICC.
Finally, we integrated with the survival function of the ICC cohort
to estimate the average durations of living under reduced
satisfaction of the HRQOL.Outcomes Research (ISPOR).
to this work.
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Collection of Sampled Subjects and Quality-of-Life Data
The study commenced after the approval of the institutional review
boards of the National Cheng Kung University Hospital (NCKUH,
institutional review board no. ER-100-314 and B-ER-102-034). Writ-
ten informed consents were obtained from every subject. Women
with a diagnosis of CIS or ICC who visited the gynecological cancer
clinic at the NCKUH were invited to participate in the study. The
study was conducted from March 2012 to September 2012. The
subjects were receiving treatment and were regularly followed at
outpatient clinics. To increase the sample size, repeated measure-
ments were taken from some subjects about 3 months apart.
According to the treatment guidelines of the NCKUH [11] for
ICC, patients with early stages of cervical cancer (stage less than
IIa) are treated with surgery with radical hysterectomy plus
bilateral pelvic lymph node dissection. Patients who had an
advanced stage ICC, the medically inoperable, or elderly patients
older than 65 years were treated with radiotherapy only or
concurrent chemoradiation. Postoperative adjuvant radiotherapy
or chemotherapy was given to patients with high risk factors for
recurrence, including deep stromal invasion, lymphovascular
space invasion, and lymph node metastasis, which were detected
from postoperation pathological reviews. Thus, there were four
groups according to their primary treatment: CIS postconization,
ICC treated with surgery only, those treated with surgery plus
chemotherapy or radiotherapy, and those treated with chemo-
therapy or radiotherapy only.
The Taiwan brief version of the World Health Organization
Quality of Life–brief version (WHOQOL-BREF) was used to measure
changes in quality of life [12]. The WHOQOL-BREF is an interna-
tionally validated instrument for gynecologic cancer [13,14] and is
designed to assess physical, psychological, social, and environ-
ment domains that affect quality of life. The method of applica-
tion, the scoring procedures, and the reference time point (during
the last 2 weeks) were the same as those of the original WHOQOL-
BREF [12]. Individual items were scored from 1 to 5 and summed
up with similar items to obtain a domain score: for example,
physical score. Each domain was transformed to the same range,
from 0 to 100, with higher scores indicating a better quality of life
[12]. Each subject was assessed by research assistants who were
formally trained in evaluating the HRQOL. Demographic and
health information was obtained through the questionnaire,
including age at diagnosis, education, marital status, and dura-
tion-to-date, as well as comorbidities, including stroke, heart
disease, diabetes mellitus, liver disease, hypertension, gastroin-
testinal disease, musculoskeletal disease, renal disease, and other
cancer. Clinical stage, pathology, and different treatments (oper-
ation, chemotherapy, or radiotherapy) were abstracted from med-
ical records as predictors of the HRQOL [7,15–17]. The duration-to-
date for each measurement was deﬁned as beginning on the ﬁrst
day after diagnosis and ending on the date of interview.Establishing the Cervical Cancer Cohort for Survival Analysis
A nationwide sample of 37,000 cases of CIS and 22,543 cases of ICC
was collected from the national cancer registry during the period
1998 to 2007. Death certiﬁcates from the National Mortality Registry
were linked to this data set to determine whether each patient was
still alive or censored on December 31, 2010. We applied the Kaplan-
Meier (K-M) method to estimate survival for these patients from the
onset of diagnosis [18] and used a semi-parametric extrapolation
method to estimate lifelong survival function, which borrows addi-
tional information from age- and sex-matched referents [19] under
the assumption of constant excess hazards [20]. The estimates wereobtained using iSQoL software, which can be freely downloaded
from theWeb [21]. Detailed methods and mathematical proofs were
described in previous studies [18–20,22,23]. After 13 years of follow-
up, the K-M’s estimate of average survival of 37,000 cases of CIS was
146.8 months, whereas that of age- and sex-matched referents
generated from the life table of Taiwan was 146.4 months. More-
over, because patients with CIS could be cured completely, we
assumed that their survival function after the end of the 13th year is
the same as that for the general population in Taiwan. The expected
years of life lost (EYLL) was estimated by calculating the difference
in life expectancy between the invasive cancer cohort and the age-
matched referents simulated from the life table of general popula-
tion of Taiwan.Estimation of Lifetime Living with Dissatisﬁed HRQOL
We applied a kernel smoothing method to the measured domain
and facet scores from cross-sectional samples for ICC and CIS
cohorts to obtain separately estimates of lifetime HRQOL func-
tions [22]. To further quantify the HRQOL reduction in patients
with ICC, we deﬁned a quality-of-life measure of relative HRQOL
score functions between patients with ICC and CIS, which is the
score ratio at time t, for a speciﬁc item (domain or facet). If the
average HRQOL score of patients with ICC is smaller than that of
those with CIS at time t, the ratio, usually a number between 0
and 1, can be interpreted as relative satisfaction of life at that
time point for patients with ICC compared with patients with CIS.
Although the integration of survival function throughout life is
the expected lifetime survival, the integration of the product of
survival function and the relative HRQOL functions gives the
expected relative-quality-adjusted survival (RQAS), which is
equivalent to the duration of living with full satisfaction as an
average person with CIS. The difference between lifetime survival
and expected RQAS in a psychometric item can be interpreted as
the expected total duration of living under a condition equivalent
to a very dissatisﬁed state in that item after the diagnosis of ICC
(see Appendix for details of derivation of this formula in Supple-
mental Materials found at http://dx.doi.org/10.1016/j.jval.2014.02.
006). We could obtain the estimates by using iSQoL software [21].
Validation of Extrapolation Method and Sensitivity Analysis
for Our Estimates
To validate our extrapolation method, we selected a subcohort of
patients with ICC between 1998 and 2003, and then extrapolated
them to the end of 2010 with the same semiparametric method,
which was compared with the K-M estimates of the actual
follow-ups. Given the K-M estimate as the criterion standard,
we calculated the relative bias for the extrapolation, deﬁned as
follows: RB ¼ (Estimate from extrapolation – K-M estimate)/K-M
estimate. Moreover, using CIS as the reference population, we
conducted sensitivity analyses to estimate the EYLL and expected
durations of dissatisﬁed years for ICC.
Statistical Analysis
Mixed-effects models were constructed assuming a linear autocor-
relation for repeated measurements within individual subjects by
using the scores for each domain and individual item as the
dependent variables, while age at interview, education (49 years/
r9 years), duration after diagnosis, aforementioned comorbidities
(yes/no), and marital status (yes/no) served as independent pre-
dictive variables. Patients classiﬁed in the CIS postconization group
were used as the reference group to explore the HRQOL changes for
different treatments of cervical cancer. A value of P o 0.05 was
regarded as signiﬁcant. All data were collected and analyzed using
version 9.2 of SAS software (SAS Institute, Cary, NC).
Table 1 – Demographic characteristics of patients with cervical cancer in the National Cheng Kung University
Hospital (NCKUH) and those registered in the cancer registry in Taiwan.
Characteristic Cancer registry (N ¼ 59,543) NCKUH (N ¼ 421) NCKUH (N ¼ 507 measurements)
Years of follow-up 1998–2007 2012 2012
Mean age  SD (y) 51.35  14.57 50.4  10.8 53.6  11.8
Carcinoma in situ 37,000 169 190
Invasive cancer, n (%)
Squamous cell carcinoma 17,868 (79.3) 198 (78.6) 248 (78.2)
Adenocarcinoma and others 4,675 (20.7) 54 (21.4) 69 (21.8)
*Including 86 repeated measurements among the original 421 patients.
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The mean duration-to-date was 64.5 months. A total of 421
patients were successfully recruited to complete the HRQOL
assessment. Sixteen percent of the patients (n ¼ 67) refused to
undergo the HRQOL assessment. Of the 421 patients, 169 were
those with CIS and the rest were those with ICC (Table 1). Eighty-
six patients (20.4%) were assessed twice roughly 3 months apart:
65 and 21 patients had ICC and CIS, respectively. As indicated in
Table 1, the demographic characteristics between the study
subjects and subjects in the Taiwan Cancer Registry were similar.
Compared with patients with CIS, all average scores of facets
in the WHOQOL-BREF of invasive cancer showed a consistent
negative sign (namely, decreased scores), and patients with ICC
treated with surgery and/or chemotherapy or radiotherapy
showed the lowest scores in both the physical and psychosocial
domains and sexual life after controlling for different predictors
in the constructed models of mixed effects (Tables 2 and 3). Given
general population as the reference group, the EYLL for an
invasive cancer was 6.48  0.03 years, while the expected very
dissatisﬁed time during the life course for the physical and
psychological domains was 1.71 and 0.25 years, respectively,
and for sexual life was 1.47 years (Figure 1). The validation result
for the semi-parametric method shows that the relative biases of
extrapolation from the end of the 6th to the 13th year was 0.4%.
We further conducted a sensitivity analysis using all 37,000 cases
of CIS as the reference for estimating the lifetime survival
function, which shows 7.11  0.04 years of EYLL; the expected
very dissatisﬁed durations were 1.79 and 0.26 years, respectively,
for the physical and psychological domains, and 1.53 years for
sexual life.Fig. 1 – The expected years of life loss (EYLL) and the
potential gain in health-related quality of life (HRQOL) for
early detection of cervical cancer. Each panel illustrates the
sum of EYLL (the area between the dotted and long-dashed
curves) and the duration of living with very dissatisﬁed
HRQOL in years (the area between the long-dashed and solid
curves) for patients with invasive cervical cancer (ICC) and
physical and psychological domains and facet of sexual life
(the score of ICC was ﬁrst divided by that of carcinoma
in situ [CIS] or referents to obtain the relative HRQOL, or,
scores ratio, indicating the degree of satisfaction with
HRQOL in comparison to patients with CIS, shown as the
dotted curve).Discussions
Few of the previous studies exploring the HRQOL changes under
different treatments for ICC used patients with CIS for score
comparison [7–10,17]. Because HRQOL is generally inﬂuenced by
different educational levels and socioeconomic states, and cer-
vical cancer is associated with human papilloma virus infection
[7,16], there might be a potential selection bias and/or incom-
parability of contrasted populations [24] if the general population
were used as referents. Thus, we deliberately selected patients
with CIS for comparison and constructed mixed-effects models to
comprehensively control potential confounders, including a sub-
ject’s education, marital status, age, and other comorbidities.
After adjustment for confounding factors, our study found a
higher score for patients with a higher education level and lower
scores for those comorbid with end-stage renal disease, which
corroborated with previous studies [15–17]. Patients with ICC had
consistently lower HRQOL in all domains and items if compared
with patients with CIS postconization, especially in pain/discom-
fort, negative feelings, self-esteem, and satisfaction with sexuallife, as also reported in previous studies [7,9,10,15,25,26] (Tables 2
and 3). Because a sensitivity analysis using CIS as an alternative
reference population to estimate lifetime survival function shows
Table 2 – Demographic characteristics and comparison of health-related quality of life from four domains with
overall score ratings in patients with cervical cancer based on the WHOQOL-BREF (mean  SD) (N ¼ 507).
Characteristic Carcinoma in situ
postconization
(N ¼ 190)
Surgery
only
(N ¼ 137)
Surgery plus
chemotherapy or
radiotherapy (N ¼ 125)
Chemotherapy or
radiotherapy only
(N ¼ 55)
Mean age  SD (y) 45  12 47  10 49  9 60  11
Stage 0, n (%) 190 (100) 0 0 0
I–IIA 0 137 (100) 110 (88) 27 (49)
IIB–IIIA 0 0 10 (8) 16 (29)
Others 0 0 5 (4) 12 (22)
Pathology, n (%)
Carcinoma in situ 190 (100) 0 0 0
Adenocarcinoma 0 23 (17) 21 (17) 4 (7)
Squamous cell carcinoma 0 112 (82) 89 (71) 47 (86)
Others 0 2 (1) 15 (12) 4 (7)
Education o9 y, n (%) 102 (54) 76 (55) 66 (53) 32 (60)
Married, n (%) 148 (78) 110 (80) 97 (78) 47 (86)
Duration  SD (mo) 66  66 65  59 66  55 62  68
Q1 overall QOL, mean  SD 3.5  0.7 3.4  0.7 3.3  0.8 3.4  0.7
Q2 overall health, mean  SD 3.4  0.8 3.0  0.9 3.1  0.8 3.2  0.8
Physical, mean  SD† 69.7  12.4 64.1  15.3 64.2  16.1 65.9  16.7
Psychological, mean  SD† 65.1  14.1 60.0  16.2 59.0  17.2 60.0  17.4
Social (Taiwan), mean  SD 62.3  15.0 61.6  14.6 62.7  15.6 58.7  16.9
Environmental (Taiwan), mean  SD 67.4  11.7 65.4  11.7 64.9  11.9 64.6  14.2
QOL, quality of life; WHOQOL-BREF, World Health Organization Quality of Life–brief version.
*One-way analysis of variance: There was a signiﬁcant difference in four groups, and Tukey post hoc comparisons showed a signiﬁcant
difference between the groups of carcinoma in situ and surgery only (P o 0.05).
†One-way analysis of variance: There was a signiﬁcant difference in four groups (P o 0.05).
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CIS plus conization would avoid any additional years of suffering
from living with very dissatisﬁed HQROL.Table 3 – Regression coefﬁcients (β^) and standard error (i
effects model for each facet and domain of the WHOQOL
Domain Facet Treatment (referen
postco
Surgery
only
Surgery
chemoth
or radiot
Physical 5.53  1.85 5.08 
Psychological 3.89  1.97 5.29 
Physical Pain and discomfort 0.40  0.12 0.57 
Mobility 0.30  0.11† 0.23 
Sleep and rest
Activities of daily
living
0.17  0.08† 0.16 
Working capacity 0.04  0.09 0.25 
Psychological Thinking, memory
and concentration
0.19  0.10 0.25 
Self-esteem 0.08  0.09 0.19 
Negative feelings 0.39  0.13* 0.29 
Social Sexual life 0.13  0.10 0.21 
Environment Opportunities for
acquiring new
skills
WHOQOL-BREF, World Health Organization Quality of Life–brief version.
* P o 0.005.
† P o 0.05.Our study does, however, have the following limitations: First,
in an ideal condition, all the HRQOL measurements should be
performed for each subject and followed longitudinallyn parentheses) based on construction of the mixed-
-BREF in patients with cervical cancer.
ce: Carcinoma in situ
nization)
Education
(Z9 y/o9 y)
Renal
disease
(yes/no)
plus
erapy
herapy
Chemotherapy
or radiotherapy
only
1.93† 4.94  2.62
2.07† 3.56  2.81 4.21  1.82†
0.13 0.32  0.17
0.11† 0.37  0.15†
0.23  0.11† 0.77  0.33†
0.08 0.15  0.11
0.09† 0.14  0.13
0.10† 0.29  0.14†
0.09† 0.03  0.13
0.14† 0.33  0.19
0.10† 0.14  0.15
0.85  0.27†
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such studies. We took an alternative approach, which was to
recruit cross-sectional, consecutive subjects from a single med-
ical center and clinic by assuming that they were randomly
drawn from all the prevalent patients with cervical cancer [22].
Because all these patients were able to come to our clinic and
their conditions at interview were generally good enough for
them to ﬁnish the interview, our results may be an overestima-
tion of the HRQOL of patients with ICC and may underestimate
the potential beneﬁt of early detection. Because our reference
subjects were taken from CIS postconization, the comparison of
contrasted populations may not be biased too much. Second,
because the quantiﬁcation of decreased HRQOL scores must be
communicated with the lay person, we have tried to conceptu-
alize the chronic proportional decrease in HRQOL item score to be
equivalent to the duration of living with a very dissatisﬁed
condition, for example, the item sexual life, with additional
assumptions similar to the conceptualization of quality-
adjusted life-year [27]. Perhaps it would be better if such a
measure of subjective preference for a speciﬁc item could be
quantiﬁed through the contingent valuation method and con-
verted to a monetary value [28] to become more user-friendly,
which would require more studies in the future.Conclusions and Policy Implications
Early detection of cervical cancer at the CIS stage not only saves
about 6.48 years of life loss but also prevents chronic reduced
satisfaction of HRQOL in the physical and psychological domains as
well as sexual life, which is tremendous considering that the
average lifespan for an invasive cancer is 20 years. In the future,
researchers may consider how much subjects are willing to pay to
estimate the monetary value of the durations of living under very
dissatisﬁed HRQOL [28], especially for the item related to sexual life.
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